AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 142 min read$REGN

UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixe

UBS upgraded Regeneron Pharmaceuticals (REGN) to Buy, citing undervaluation and a strong pipeline of next-gen Dupixent candidates. The firm set a $978 price target, implying 30% upside from the recent close of $778.36. Regeneron's GF Value is $923.58, suggesting 15.7% undervaluation. The company's GF Score is 87/100, reflecting robust financial health and profitability. Insiders have sold $12.9M in shares over the past year, while institutional guru ownership remains high.

Original reporting
gurufocus.com
Published Oct 14, 2026, 9:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The UBS upgrade provides a fresh valuation perspective, likely prompting short‑term buying and re‑rating by other analysts.

02

Market read

A new analyst upgrade with a specific price target can move a mid‑cap biotech stock, making the story relevant for short‑term traders.

03

What to watch

Potential patent expirations and competition in the immunology space could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Regeneron is a large‑cap biotech with flagship products Dupixent and Eylea; the upgrade focuses on upcoming Dupixent candidates.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

UBS upgraded Regeneron to Buy with a $978 price target, citing undervaluation and next‑gen Dupixent pipeline.

Expected impact

upward pressure as investors price in the new target and pipeline upside

Evidence & confidence

Analyst upgrade with a concrete price target and 30% upside estimate typically moves the stock in the short term.

Market effects

Sector

Biotech sector may see modest rally as the upgrade highlights pipeline potential.

Regional

U.S. markets could see slight uplift in healthcare indices.

Global

Limited to investors tracking U.S. biotech stocks.

Counterpoint

What could challenge this read

Insider selling and modest momentum score suggest caution; the upgrade may be premature.

Key entities

  • company
    Regeneron Pharmaceuticals Inc

    Biotech firm developing next‑gen Dupixent candidates.

  • analyst
    UBS

    Investment bank that issued the Buy upgrade and $978 price target.

Read at source← All news

StoryUBS upgrades Regeneron to Buy and sets $978 price target

Related articles

OCT 13
$REGNMedAI 9/10

Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Regeneron Pharmaceuticals reported 84-week Phase III trial data for Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The trial showed Pasatru prevented new heterotopic ossification lesions and reduced flare-ups compared to placebo. Safety data remained consistent, with no deaths reported. Regulatory submissions are planned in several countries, including Japan.

finance.yahoo.com2 min
OCT 13
$REGNMed

Regeneron presents new long-term data for Pasatru

Regeneron Pharmaceuticals (Nasdaq: REGN) reported 84-week Phase III trial results for Pasatru (garetosmab-grts) in treating fibrodysplasia ossificans progressiva (FOP). The data showed sustained efficacy in stopping new bone growth and reducing flare-ups. REGN shares closed up 2.2% at $762.81 after the announcement. The findings were presented at the ASBMR Annual Meeting.

thepharmaletter.com3 min
OCT 12
Med

Regeneron Pharmaceuticals, Inc. Announces Positive 84-Week Results From Phase 3 OPTIMA Trial Evaluating Pasatru In Adults With Fibrodysplasia Ossificans Progressiva

Regeneron announced 84-week results from its Phase 3 OPTIMA trial for Pasatru in adults with FOP, showing sustained efficacy in halting new bone growth and reducing flare-ups. The trial met its primary endpoint at 56 weeks and maintained results at 84 weeks. Pasatru was recently FDA-approved based on 56-week data. Regeneron plans to start a Phase 3 trial for adolescents and children with FOP later this year.

marketscreener.com2 min
OCT 12
$REGNMed

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.

finance.yahoo.com5 min